ANTIBIOTIC RESISTANCE RATES OF BACTERIAL ISOLATES FROM URINARY TRACT INFECTIONS IN DIABETIC PATIENTS IN SANA’A, YEMEN
Keywords:
Antimicrobial resistance, diabetes mellitus, empirical treatment, Escherichia coli, Klebsiella, Pseudomonas aeruginosa, uropathogensAbstract
Background and aims: Urinary tract infections (UTIs) are among the most common bacterial infections, particularly among diabetic patients. These infections are often complicated by antibiotic resistance and the patients' susceptibility to infection, making empirical treatment difficult. This study was conducted to identify the pattern of antibiotic resistance in UTI pathogens among diabetic patients in the medical ward of Kuwait Hospital in Sana'a, Yemen, with the aim of improving the empirical treatment of UTIs with antibiotics.
Materials and Methods: Total 454 DM patients were sent to the medical ward of the Al-Kwait University Hospital clinics in Sana'a, Yemen, for this cross-sectional study. In order to perform a urine culture, a clean, sterile urine sample (midstream pee) was collected, cultured, and the pathogenic bacteria were isolated and identified.
Results: The mean patient age was 48.2 years, with 73.1% being ≥ 40 years old. Escherichia coli caused 41 (42%) of UTIs, Klebsiella pneumoniae 33 (34%), Pseudomonas aeruginosa 9 (9.3%), and Enterococcus faecalis 6 (6.2%).Resistance rates in E. coli are high, reaching 95% for amoxicillin and 70.7% for ampicillin, with varying levels of resistance for other antibiotics, ranging from 36.6% to 92.7% for agents like ceftazidime and ciprofloxacin. Low resistance rates were noted for amikacin (4.9%) and other select antibiotics. Klebsiella pneumoniae displayed 100% resistance to amoxicillin and ampicillin, with lower resistance rates for amikacin (0%) and levofloxacin (18.2%).
Conclusions: The increasing resistance of antibiotics highlights the need for up-to-date local data to guide empirical treatment for urinary tract infections (UTIs). Amikacin, cefotaxime, levofloxacin, lomefloxacin , clarithromycin, ciprofloxacin, piperacillin-tazobactam, and tobramycinhave demonstrated low resistance rates and could be an effective first-line treatment for UTIs at Al-Kuwait Hospital.
Peer Review History:
Received 4 February 2026; Reviewed 9 March 2026; Accepted 17 April; Available online 15 May 2026
Academic Editor: Dr. A.A. Mgbahurike
, University of Port Harcourt, Nigeria, [email protected]
Reviewers:
Dr. Alfonso Alexander Aguileral, University of Veracruz, Mexico, [email protected]
Dr. Gülay B Anadolu, Anadolu University, Eskisehir, Turkey, [email protected]
Downloads
Published
How to Cite
Issue
Section
Copyright (c) 2026 Universal Journal of Pharmaceutical Research

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.




.